ERBB2 and neoplasm: Recently, a strong TLR8 agonist, combined with a HER2 monoclonal antibody was designed (sbt-6050), aiming to activate myeloid cells with the presence of HER2 positive tumor cells, and it is under investigation now in HER2 positive solid tumors with pembrolizumab (NCT04460456).